乳腺癌CD44和nm23基因表达与侵袭转移的关系

目的：探讨粘附分子CD44和抑癌基因nm23与乳腺癌侵袭转移的关系。方法：采用逆转录聚合酶链反应（RT－PCR）方法对30例乳腺癌及10例乳腺良性肿瘤组织中CD44V6和nm23-H1基因的表达进行检测,结果：乳腺癌组织中CD44V6及nm23-H1的表达明显高于乳腺良性肿瘤;CD44V6和nm23-H1的阳性表达与乳腺癌的临床分期和是否有淋巴结转移密切相关,而与乳腺癌的病理类型无关。结论：CD44V6和nm23-H1异常表达是乳腺癌发生发展,浸润转移的重要分子学改变。同时检测两者可更好地预测其进展程度和对淋巴结转移的判断。     

膀胱癌P21、P53、nm23蛋白表达的临床意义

目的探讨癌基因与抑癌基因表达与膀胱癌生物学行为的关系.方法应用免疫组化方法对48例膀胱移行细胞癌中P21、P53、nm23蛋白进行检测.结果P21、P53、nm23蛋白表达的阳性率分别是58.3%、47.9%、41.7%.P21、P53蛋白表达阳性率与肿瘤分级、分期及复发呈正相关.nm23蛋白表达阳性率与分级呈正相关,与分期及复发呈负相关.77.1%膀胱癌有上述蛋白异常表达,其中47.9%膀胱癌同时有两个或两个以上蛋白表达.结论癌基因及抑癌基因的异常表达及协同作用,在膀胱癌发生、发展中起重要作用.     

胃癌组织中nm23蛋白表达与微血管密度及其转移的关系研究

目的探讨胃癌组织中nm23蛋白的表达与癌组织微血管密度与转移的关系.方法用免疫组织化学LSAB方法检测85例胃癌癌组织微血管(MVD)及mn23蛋白的表达;在第Ⅶ因子相关抗原(FⅦRAg)染色切片上检测其微血管密度.结果nm23表达阳性淋巴结转移率明显低于nm23表达阴性组,而且差异有显著性.nm23表达阳性组与阴性组比较,nm23表达与MVD呈负相关.结论nm23基因受抑制时,MVD增加,淋巴结转移率增高.因此时nm23及MVD的检测,可作为预测胃癌转移及判断预后的可靠指标之一.     

nm23—H1基因表达与乳腺癌侵袭转移的关系

目的：探讨肿瘤抑制基因（nm23-H1）的表达与乳腺癌浸润转移的关系,方法：采用免疫组织化学及反转录一多聚酶链反应（RT－PCR）方法对30例乳腺癌及10例乳腺良性肿瘤中nm23-H1基因产物的表达进行研究,结果：nm23-H1在乳腺癌组织中的表达明显高于良性组织,早期乳腺癌（Ⅰ-Ⅱ期）nm23-H1阳性表达率明显高于中晚期乳腺癌（Ⅲ-Ⅳ）,有淋巴结转移的乳腺癌组织中nm23-H1阳性表达率显著低于无淋巴结转移者;nm23-H1的表达与乳腺癌的病理类型无关,结论：nm23-H1异常表达可能是乳腺癌浸润转移的重要分子学标志,检测乳腺癌组织nm23-H1的表达,有助于预测其进展程度和对淋巴结转移的判断。     

CD44v6和nm23-H_1的表达对大肠癌淋巴结转移的影响

目的　探讨CD44v6和nm2 3-H1基因产物表达与大肠癌淋巴结转移的关系。方法　应用SP免疫组化染色法 ,对 76例大肠癌标本进行CD44v6和nm2 3-H1基因产物测定。结果　CD44v6基因产物的高表达和nm2 3-H1基因产物的低表达与大肠癌淋巴结转移有关 (P <0 .0 1)。大肠癌CD44v6和nm2 3-H1表达无相关性 (P >0 .0 5 ) ,但CD44v6阳性表达伴nm2 3-H1阴性表达的患者发生淋巴结转移的可能性大。结论　CD44v6和nm2 3-H1与大肠癌淋巴结转移密切相关 ,两者在淋巴结转移中起协同作用 ,联合检测对判断大肠癌淋巴结转移是一个有用的指标。     

Burosumab for the Treatment of Tumor-Induced Osteomalacia

Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. UX023T-CL201 is an ongoing, open-label, phase 2 study investigating the safety and efficacy of burosumab, a fully human monoclonal antibody that inhibits FGF23, in adults with TIO or cutaneous skeletal hypophosphatemia syndrome (CSHS). Key endpoints were changes in serum phosphorus and osteomalacia assessed by transiliac bone biopsies at week 48. This report focuses on 14 patients with TIO, excluding two diagnosed with X-linked hypophosphatemia post-enrollment and one with CSHS. Serum phosphorus increased from baseline (0.52 mmol/L) and was maintained after dose titration from week 22 (0.91 mmol/L) to week 144 (0.82 mmol/L, p < 0.0001). Most measures of osteomalacia were improved at week 48: osteoid volume/bone, osteoid thickness, and mineralization lag time decreased; osteoid surface/bone surface showed no change. Of 249 fractures/pseudofractures detected across 14 patients at baseline, 33% were fully healed and 13% were partially healed at week 144. Patients reported a reduction in pain and fatigue and an increase in physical health. Two patients discontinued: one to treat an adverse event (AE) of neoplasm progression and one failed to meet dosing criteria (receiving minimal burosumab). Sixteen serious AEs occurred in seven patients, and there was one death; all serious AEs were considered unrelated to treatment. Nine patients had 16 treatment-related AEs; all were mild to moderate in severity. In adults with TIO, burosumab exhibited an acceptable safety profile and was associated with improvements in phosphate metabolism and osteomalacia. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research..     

经尿道国产1470nm激光汽化术治疗<30g小体积前列腺增生的临床体会

目的探讨经尿道国产1470nm激光汽化术治疗<30g小体积前列腺增生患者的安全性、有效性和远期并发症情况。方法回顾性研究2017年10月至2018年9月我院45例<30g小体积前列腺增生患者的临床资料,其中TURP组20例,1470 nm激光组25例。详细记录两组患者的临床资料、围手术期并发症和随访情况。结果45例患者手术均成功,术后平均随访时间12.6个月(9~16个月)。两组患者年龄、前列腺体积和IPSS、RUV、Qmax和QOL基线资料差异无统计学意义(P>0.05)。TURP组和1470 nm激光组患者术后3个月IPSS、RUV、Qmax和QOL均较术前改善(P<0.05),组间比较差异无统计学意义(P>0.05)。1470 nm激光组患者手术时间([48.6±13.6)min vs(56.8±11.7)min,P=0.038]、术后膀胱持续冲洗时间[(0.8±0.5)d vs(1.5±0.9)d,P=0.001]、导尿管留置时间([2.7±0.6)d vs(4.7±0.9)d,P<0.001]和住院时间([4.2±1.2)d vs(5.2±1.9)d,P=0.036]较TURP组患者明显缩短,术前术后血红蛋白浓度变化更小([5.5±2.4)g/L vs(11.6±2.7)g/L,P<0.01]。随访发现TURP组有2例出现尿道狭窄,1470 nm激光组无尿道狭窄病例发生。结论经尿道国产1470 nm激光汽化术治疗<30 g小体积前列腺增生安全有效,与传统TURP比较术中出血少,术后恢复时间更短,无尿道狭窄并发症发生,为BPH的个体化治疗提供了新的思路。